PMC:7558914 / 13729-14030 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T11","span":{"begin":89,"end":96},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T12","span":{"begin":89,"end":96},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"}],"text":"In 8 of the 15 COVID-19 protocols (53.3%), the dose of prophylactic low-molecular-weight heparin was increased if there was a high risk of thrombosis (severe COVID-19 with evidence of cytokine release syndrome, previous venous thromboembolism or acute ischemic artery disease, or D-dimer \u003e3000 ng/mL)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"333","span":{"begin":89,"end":96},"obj":"Chemical"},{"id":"338","span":{"begin":15,"end":23},"obj":"Disease"},{"id":"339","span":{"begin":139,"end":149},"obj":"Disease"},{"id":"340","span":{"begin":158,"end":166},"obj":"Disease"},{"id":"341","span":{"begin":220,"end":242},"obj":"Disease"},{"id":"342","span":{"begin":246,"end":275},"obj":"Disease"}],"attributes":[{"id":"A333","pred":"tao:has_database_id","subj":"333","obj":"MESH:D006493"},{"id":"A338","pred":"tao:has_database_id","subj":"338","obj":"MESH:C000657245"},{"id":"A339","pred":"tao:has_database_id","subj":"339","obj":"MESH:D013927"},{"id":"A340","pred":"tao:has_database_id","subj":"340","obj":"MESH:C000657245"},{"id":"A341","pred":"tao:has_database_id","subj":"341","obj":"MESH:D054556"},{"id":"A342","pred":"tao:has_database_id","subj":"342","obj":"MESH:D014715"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In 8 of the 15 COVID-19 protocols (53.3%), the dose of prophylactic low-molecular-weight heparin was increased if there was a high risk of thrombosis (severe COVID-19 with evidence of cytokine release syndrome, previous venous thromboembolism or acute ischemic artery disease, or D-dimer \u003e3000 ng/mL)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":184,"end":209},"obj":"Phenotype"},{"id":"T25","span":{"begin":227,"end":242},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0001907"}],"text":"In 8 of the 15 COVID-19 protocols (53.3%), the dose of prophylactic low-molecular-weight heparin was increased if there was a high risk of thrombosis (severe COVID-19 with evidence of cytokine release syndrome, previous venous thromboembolism or acute ischemic artery disease, or D-dimer \u003e3000 ng/mL)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T94","span":{"begin":0,"end":301},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In 8 of the 15 COVID-19 protocols (53.3%), the dose of prophylactic low-molecular-weight heparin was increased if there was a high risk of thrombosis (severe COVID-19 with evidence of cytokine release syndrome, previous venous thromboembolism or acute ischemic artery disease, or D-dimer \u003e3000 ng/mL)."}